Advertisement
Advertisement
ORKA
Oruka Therapeutics, Inc. Common Stock
60.12
USDSponsored
+0.54
+0.91%
Apr 13, 13:22 UTC -4
Open
ORKA Earnings Reports
Positive Surprise Ratio
ORKA beat 16 of 17 last estimates.
94%
Next Report
Date of Next Report
May 12, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/-$0.56
Implied change from Q4 25 (Revenue/ EPS)
--
/+24.44%
Implied change from Q1 25 (Revenue/ EPS)
--
/+40.00%
Oruka Therapeutics, Inc. Common Stock earnings per share and revenue
On Mar 12, 2026, ORKA reported earnings of -0.45 USD per share (EPS) for Q4 25, beating the estimate of -0.64 USD, resulting in a 29.69% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +25.04% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 11 analysts forecast an EPS of -0.56 USD, with revenue projected to reach -- USD, implying an increase of 24.44% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Centessa Pharmaceuticals plc - ADR
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.38
Actual
-$0.48
Surprise
-23.58%
Lexeo Therapeutics, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.32
Actual
-$0.27
Surprise
+15.84%
AleAnna, Inc. Class A Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-Actual
$0.00
Surprise
-
Unicycive Therapeutics, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.48
Actual
-$0.81
Surprise
-69.64%
Galectin Therapeutics Inc.
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.08
Surprise
+21.57%
Cardiol Therapeutics Inc. Class A Common Shares
Report Date
Apr 01, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.07
Surprise
+14.22%
Actinium Pharmaceuticals, Inc
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.20
Surprise
-5.04%
Jupiter Neurosciences, Inc. Common Stock
Report Date
Apr 01, 2026 For Q4 25
Estimate
-$0.07
Actual
-$0.06
Surprise
+6.16%
Scienture Holdings, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.28
Actual
-$0.11
Surprise
+61.48%
60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$2.32
Actual
-$2.34
Surprise
-0.62%
FAQ
What were Oruka Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Oruka Therapeutics, Inc. Common Stock reported EPS of -$0.45, beating estimates by 29.69%, and revenue of $0.00, 0% as expectations.
How did the market react to Oruka Therapeutics, Inc. Common Stock's Q4 2025 earnings?
The stock price moved up 25.04%, changed from $31.99 before the earnings release to $40.00 the day after.
When is Oruka Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 12, 2026.
What are the forecasts for Oruka Therapeutics, Inc. Common Stock's next earnings report?
Based on 11
analysts, Oruka Therapeutics, Inc. Common Stock is expected to report EPS of -$0.56 and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement